The U.S. Food and Drug Administration (FDA) has announced a new initiative aimed at accelerating the repurposing of already approved medicines to treat diseases with significant unmet medical needs, including rare disorders, neurodegenerative diseases, metabolic conditions, and substance use disorders.

OneSource Specialty Pharma Limited has announced a strong recovery in its fourth quarter performance for FY26, driven by growth across all major business segments and the commercial launch of semaglutide products in India. The company also reaffirmed its FY28 guidance of achieving nearly USD 400 million in organic revenue with around 40% EBITDA margin.

-- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen.

Centurion University’s School of Pharmacy and Life Sciences (SoPLS) is an institution established on 2016 dedicated to touch human lives in healthcare and happiness to ensure holistic societal development through skill based education, research, drug development and community welfare services, SoPLS committed to undertake the task of meeting professional and social needs like identification, cure, mitigation of disease and innovative drug design. It focuses in fulfiling student’s career in pharmaceutical sector, research and entrepreneurship.

Applications are invited for the position of Project Research Scientist-II (Non-Medical) in the ICMR funded project titled “A Randomized Trial of Enhanced Immunosuppression versus antifibrotic therapy and drug response prediction in progressive pulmonary fibrosis (RUNNER trial). (Project Code 1-1872) on temporary basis.

Post : Project Research Scientist-II I (Non- Medical)

Macleods is one of the fastest growing pharmaceutical company, having strong presence in various therapeutics segments. Ranked amongst the top 10 companies.

WALK IN FRESHER

For more than 60 years. Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world's most discerning drug regulatory authorities like UK-MHRA. EDQM-Europe. and WHO Geneva, among others.

A newly introduced drug approval pathway in the United Kingdom is facing criticism from healthcare experts, who argue that the system may favor pharmaceutical companies more than patients or the public healthcare system. According to an analysis published in The BMJ, the accelerated process could lead to quicker market access for medicines without guaranteeing meaningful benefits for patients.

People who have survived a heart attack could be at a greater risk of experiencing faster declines in memory and thinking abilities as they age, according to a new study published in the journal Stroke.

Researchers found that adults with a prior heart attack had a significantly higher likelihood of developing cognitive impairment over time compared to individuals without a history of heart attack. The findings highlight a growing connection between heart health and brain health, especially among older adults.